Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 13,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs

NCT07038785
View directory record Official record
Conditions
Breast Cancer
Interventions
Breath test
Diagnostic Test
Lead sponsor
SpotitEarly
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Totowa, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Not listed Phase 2 Interventional

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
Interventions
Liraglutide 6 mg Solution for Injection, Placebo
Drug · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Photocil (Topical) for the Treatment of Vitiligo

NCT01992185
View directory record Official record
Conditions
Vitiligo
Interventions
Photocil for Vitiligo, Placebo - Sunscreen (SPF 2)
Drug · Other
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 28, 2026, 10:22 AM EDT
Not listed Phase 2 Interventional

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00036998
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, neoadjuvant therapy, thermal ablation therapy
Procedure
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Coral Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Carboplatin, Paclitaxel, Bevacizumab, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

NCT02361216
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

NCT00004104
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
liposomal interleukin-2, polyvalent melanoma vaccine, recombinant interferon alfa
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

NCT01033552
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Cyclophosphamide, Fludarabine, Anti-thymocyte globulin, Myeloablative Busulfan, Mesenchymal stem cell transplantation, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer

NCT02590458
View directory record Official record
Conditions
Breast Cancer
Interventions
Short Breast MRI (SBMRI), Questionnaire
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

NCT05812781
View directory record Official record
Conditions
Cryopyrin Associated Periodic Syndrome
Interventions
VTX2735
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Diego, California • Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

NCT02174419
View directory record Official record
Conditions
Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions
nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 28, 2026, 10:22 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Vaginal Ecosystem and Network in the United States Study

NCT06472765
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions
Vaginal Swab Collection
Diagnostic Test
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
3,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

Exercise to ReGain Stamina and Energy (The EXERGISE Study)

NCT05684367
View directory record Official record
Conditions
Fatigue, Breast Cancer, Cancer, Therapy-Related
Interventions
Center-Based Walking Exercise, Home-Based Walking Exercise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 105 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

NCT00327600
View directory record Official record
Conditions
Malignant Melanoma
Interventions
imexon, DTIC
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362
View directory record Official record
Conditions
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions
BT8009, Pembrolizumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662
View directory record Official record
Conditions
Breast Cancer
Interventions
HKI-272, Surgical Resection, Capecitabine, Ado-Trastuzumab Emtansine
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

SAVE Trial: SAfe Opioid Use Video Education

NCT07044583
View directory record Official record
Conditions
Breast Reconstruction, Breast Cancer
Interventions
Opioid Educational Video
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

NCT01276041
View directory record Official record
Conditions
Breast Cancer
Interventions
pertuzumab in combination with trastuzumab and paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

NCT04109456
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IN10018, Cobimetinib, Atezolizumab
Drug · Biological
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational Results available

Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

NCT01197456
View directory record Official record
Conditions
Breast Cancer, Ovarian Insufficiency, Ovarian Failure
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

NCT00445445
View directory record Official record
Conditions
Breast Cancer
Interventions
physiologic testing, screening questionnaire administration, breast imaging study, radiomammography, study of high risk factors
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
2,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
8
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio • Mentor, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 28, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects

NCT03897270
View directory record Official record
Conditions
Breast Carcinoma, Healthy Subject
Interventions
Photoacoustic Imaging
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Human Factors Testing for OTC Use of the Erchonia® LunulaLaser

NCT05626270
View directory record Official record
Conditions
Onychomycosis
Interventions
LunulaLaser OTC
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 28, 2026, 10:22 AM EDT